Payment overview · 2025
General Payments
$376.97
18 reported records · 5 companies
Healthcare provider profile · identity verified
Trevor Short, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ZANESVILLE, OH · NPI 1891115648
Verified facts
What the public records show
CMS Open Payments records show Trevor Short, M.D. received $376.97 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 49.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Synthroid by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $188.03 | 49.9% | 14 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $132.72 | 35.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $26.81 | 7.1% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $15.04 | 4.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.37 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $376.97 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $132.72 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $121.41 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.00 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.62 | 6 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $26.81 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
121 | 34 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 892 | 267 |
| Amlodipine Besylate | Amlodipine Besylate | 607 | 182 |
| Pantoprazole Sodium | Pantoprazole Sodium | 563 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 542 | 132 |
| Lisinopril | Lisinopril | 503 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 447 | 111 |
| Losartan Potassium | Losartan Potassium | 407 | 119 |
| Hydrochlorothiazide | Hydrochlorothiazide | 374 | 108 |
| Omeprazole | Omeprazole | 369 | 100 |
| Gabapentin | Gabapentin | 350 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 335 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 289 | 78 |
| Metformin Hcl | Metformin Hcl | 258 | 73 |
| Sertraline Hcl | Sertraline Hcl | 234 | 60 |
| Potassium Chloride | Potassium Chloride | 224 | 63 |
| Alprazolam | Alprazolam | 223 | 59 |
| Alendronate Sodium | Alendronate Sodium | 208 | 57 |
| Simvastatin | Simvastatin | 207 | 57 |
| Furosemide | Furosemide | 197 | 67 |
| Buspirone Hcl | Buspirone Hcl | 170 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 44 |
| Prednisone | Prednisone | 158 | 109 |
| Atenolol | Atenolol | 155 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 46 |
| Carvedilol | Carvedilol | 149 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 38 |
| Trazodone Hcl | Trazodone Hcl | 148 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 67 |
| Allopurinol | Allopurinol | 143 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 140 | 47 |
| Glimepiride | Glimepiride | 134 | 32 |
| Eliquis | Apixaban | 130 | 34 |
| Synthroid | Levothyroxine Sodium | 121 | 34 |
| Ezetimibe | Ezetimibe | 116 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 114 | 97 |
| Metformin Hcl Er | Metformin Hcl | 114 | 31 |
| Ozempic | Semaglutide | 111 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 30 |
| Meloxicam | Meloxicam | 102 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 101 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 100 | 27 |
| Farxiga | Dapagliflozin Propanediol | 97 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 27 |
| Nifedipine Er | Nifedipine | 91 | 22 |
| Finasteride | Finasteride | 90 | 27 |
| Trulicity | Dulaglutide | 90 | 13 |
| Montelukast Sodium | Montelukast Sodium | 88 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 22 |
| Spironolactone | Spironolactone | 79 | 26 |
| Methylprednisolone | Methylprednisolone | 77 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 26 |
| Celecoxib | Celecoxib | 74 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 20 |
| Bupropion Xl | Bupropion Hcl | 71 | 25 |
| Famotidine | Famotidine | 71 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 16 |
| Pregabalin | Pregabalin | 69 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 20 |
| Mirtazapine | Mirtazapine | 66 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 54 |
| Cephalexin | Cephalexin | 64 | 44 |
| Tramadol Hcl | Tramadol Hcl | 62 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 27 |
| Clonazepam | Clonazepam | 47 | 11 |
| Lorazepam | Lorazepam | 47 | 16 |
| Lovastatin | Lovastatin | 47 | 11 |
| Jardiance | Empagliflozin | 44 | 12 |
| Linzess | Linaclotide | 44 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 12 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 13 |
| Klor-Con M20 | Potassium Chloride | 42 | 16 |
| Xarelto | Rivaroxaban | 42 | 12 |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | 13 |
| Meclizine Hcl | Meclizine Hcl | 37 | 25 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 37 | 11 |
| Warfarin Sodium | Warfarin Sodium | 37 | 14 |
| Enalapril Maleate | Enalapril Maleate | 36 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 25 |
| Irbesartan | Irbesartan | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 14 |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Repatha Syringe | Evolocumab | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 13 |
| Digoxin | Digoxin | 26 | suppressed |
| Nystatin | Nystatin | 26 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Potassium Citrate Er | Potassium Citrate | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Indapamide | Indapamide | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 15 |
| Fluocinonide | Fluocinonide | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Pimecrolimus | Pimecrolimus | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Tretinoin | Tretinoin | 12 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $376.97 · 18 records | ABBVIE INC. | CDS - MCT/CEM Monitoring, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), GEMTESA, QULIPTA, TREMFYA, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error